A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

This study is testing a new drug called Tolododekin Alfa (ANK-101), given alongside an existing immunotherapy drug, in people with advanced non-small cell lung cancer (a common type of lung cancer that has spread). **You may be eligible if:** - You have been diagnosed with locally advanced or metastatic non-small cell lung cancer - You have measurable tumors on imaging scans - You are in good physical health and expected to live more than 12 weeks - Your thyroid hormone levels and heart function are normal - You are willing to use effective contraception **You may NOT be eligible if:** - You have received prior immunotherapy treatment - You have a serious heart condition or significantly prolonged heart rhythm - You have active autoimmune disease requiring treatment - You are pregnant or breastfeeding - You have active brain metastases that are untreated or unstable Talk to your doctor to see if this trial is right for you.